Effect of the inhibition of CYP3A4 or CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone

被引：0
|
作者：
Oliver Kummer
Felix Hammann
Claudine Moser
Olivier Schaller
Jürgen Drewe
Stephan Krähenbühl
机构：
[1] University Hospital,Division of Clinical Pharmacology and Toxicology, Department of Biomedicine
[2] Mundipharma Medical Company,undefined
来源：
European Journal of Clinical Pharmacology | 2011年 / 67卷
关键词：
Oxycodone; Ketoconazole; Paroxetine; Drug interactions; Pharmacokinetics; Pharmacodynamics;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：63 / 71
页数：8
相关论文
共 50 条
  • [41] Effect of CYP2D6 genetic polymorphism on the population pharmacokinetics of tipifarnib
    Perez-Ruixo, Juan Jose
    Zannikos, Peter
    Ozdemir, Vural
    Franc, Monique A.
    Francke, Stephan
    Piotrovsky, Vladimir
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 58 (05) : 681 - 691
  • [42] Effect of Strong CYP3A4 Inhibition, CYP3A4 Induction, and OATP1B1/3 Inhibition on the Pharmacokinetics of a Single Oral Dose of Sotorasib
    Cardona, Panli
    Dutta, Sandeep
    Houk, Brett
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2024, 13 (07): : 810 - 818
  • [43] The Effects of CYP3A4 Induction and Inhibition on the Pharmacokinetics of Alisporivir in Humans
    Barve, Avantika
    Kovacs, Steven J.
    Ke, June
    Crabbe, Rafael
    Grosgurin, Peter
    Menetrey, Annick
    Nicolas-Metral, Valerie
    Dabovic, Kristina
    Dole, Kiran
    Zhang, Jie
    Praestgaard, Jens
    Sunkara, Gangadhar
    Stein, Daniel
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2015, 4 (01): : 25 - 32
  • [44] Impact of CYP2D6 polymorphisms on the pharmacokinetics of lovastatin in Chinese subjects
    Yin, Ophelia Qi Ping
    Mak, Valiant Wah Lun
    Hu, Miao
    Fok, Benny Siu Pong
    Chow, Moses Sing Sum
    Tomlinson, Brian
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 68 (06) : 943 - 949
  • [45] Response to hydrocodone, codeine and oxycodone in a CYP2D6 poor metabolizer
    Susce, Margaret T.
    Murray-Carmichael, Elaina
    de Leon, Jose
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2006, 30 (07) : 1356 - 1358
  • [46] The Hypoalgesic Effect of Oxycodone in Human Experimental Pain Models in Relation to the CYP2D6 Oxidation Polymorphism
    Zwisler, Stine T.
    Enggaard, Thomas P.
    Noehr-Jensen, Lene
    Pedersen, Rasmus S.
    Mikkelsen, Soeren
    Nielsen, Flemming
    Brosen, Kim
    Sindrup, Soeren H.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2009, 104 (04) : 335 - 344
  • [47] The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine
    Azuma, Junichi
    Hasunuma, Tomoko
    Kubo, Masanori
    Miyatake, Masaya
    Koue, Toshiko
    Higashi, Koushi
    Fujiwara, Tsutomu
    Kitahara, Sachiko
    Katano, Tamiki
    Hara, Sumiko
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 68 (01) : 29 - 37
  • [48] The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine
    Junichi Azuma
    Tomoko Hasunuma
    Masanori Kubo
    Masaya Miyatake
    Toshiko Koue
    Koushi Higashi
    Tsutomu Fujiwara
    Sachiko Kitahara
    Tamiki Katano
    Sumiko Hara
    European Journal of Clinical Pharmacology, 2012, 68 : 29 - 37
  • [49] Impact of the CYP2D6 genotype on post-operative intravenous oxycodone analgesia
    Zwisler, S. T.
    Enggaard, T. P.
    Mikkelsen, S.
    Brosen, K.
    Sindrup, S. H.
    ACTA ANAESTHESIOLOGICA SCANDINAVICA, 2010, 54 (02) : 232 - 240
  • [50] Effect of CYP2D6 genetic polymorphism on peak propafenone concentration: no significant effect of CYP2D6*10
    Doki, Kosuke
    Shirayama, Yuki
    Sekiguchi, Yukio
    Aonuma, Kazutaka
    Kohda, Yukinao
    Ieda, Masaki
    Homma, Masato
    PHARMACOGENOMICS, 2020, 21 (18) : 1279 - 1288
12345